Central Rennin-angiotensin System and Alzheimer's Disease

Abstract

Abstract: Alzheimer's disease (AD) is not only a global major public health issue of common concern, but also an increasingly serious social problem. Developing novel prevention or treatment targets and drugs of AD is an arduous task that remains to be overcome. More and more studies show that central rennin-angiotensin system (CRAS) is closely associated with AD. Based on related literatures, we reviewed the roles of Ang II and its receptors (AT₁R and AT₂R), Ang Ⅳ and its receptor (AT₄R) as well as ACE in AD, and revealed potential targets, and indicated new directions to developing drugs for AD.

Key words: Alzheimer's disease (AD), angiotensin II type 1 receptor (AT₁R), angiotensin II type 2 receptor (AT₂R), angiotensin II type 4 receptor (AT₄R), angiotensin converting enzyme (ACE)

CLC Number:

R964

WANG Chao，XIANG Guo-qing，HONG Hao. Central Rennin-angiotensin System and Alzheimer's Disease[J]. Acta Neuropharmacologica, 2012, 2(2): 37-41.

References

[1] Henry W Querfurth, Frank M LaFerla. Alzheimer's disease [J]. N Engl J Med, 2010, 362(4): 329-344.

[2] Nathan Herrmann, Sarah A Chau, Ida Kircanski, et al. Current and emerging drug treatment options for Alzheimer's disease: a systematic review [J]. Drugs, 2011, 71(15): 2031-2065.

[3] Martin Paul, Ali Poyan Mehr, Reinhold Kreutz. Physiology of local Renin-Angiotensin Systems [J]. Physiol Rev, 2006, 86(3): 747-803.

[4] John W Wright, Joseph W Harding. The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory [J]. Prog Neurobiol, 2004, 72(4): 263-293.

[5] Unger T, Badoer E, Ganten D, et al. Brain angiotensin: Pathway and pharmacology [J]. Circulation, 1988, 77(6 Pt 2): 140-154.

[6] Paul M, Printz M, Harns E. Loculation of renin and converting enzyme in nerve endings of rat [J]. Brain Res, 1985, 334(2): 315-322.

[7] Victor J Dzau, Burt D W, Richard E Pratt. Molecular biology of the rennin angiotensin system [J]. Am J Physiol, 1988, 255(4): F563-573.

[8] Victor J Dzau, Julie Ingelfinger, Richard E Pratt, et al. Identification of rennin and angiotensinogen messenger RNA sequences in mouse and rat brains [J]. Hypertension, 2009, 78(6):544-551.

[9] Manwen Jim, Markus J Wilhelm, Rudolf E Lang. Endogenous tissure rennin-angiotensin systems From molecular biology to therapy [J]. Am J Med, 1988, 84(3A): 28-36.

[10] Michael B Gutman, Douglas L Jones, John Ciriello. Effect of paraventricular nucleus lesions of drinking and pressor responses to ANG II [J]. Am J Physiol (Regul Intergr Conp Physiol), 1988, 255(6 Pt 2): 145-163.

[11] Egemen Savaskan, Christoph Hock, Gianfranco Olivieri, et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia [J]. Neurobiol Aging, 2011, 22(4): 541–546.

[12] Savaskan E, Hochli M, Ganten D, et al. Angiotensin II immunoreactivity in the human striatum and hippocampus of elderly controls and patients with senile dementia of the Alzheimer type and multi-infarct dementia [J]. Dement Geriatr Cogn Disord, 1991, 2: 314–323.

[13] Dimitri De Bundel, IIse Smolders, Patrick Vanderheyden, et al. Ang II and Ang IV: unraveling the mechanism of action on synaptic plasticity, memory, and epilepsy [J].CNS Neurosci Ther, 2009, 15(2): 315-339.

[14] Zhu Dong-lin, Shi Jing-ping, Zhang Ying-dong, et al. Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats [J]. PLoS One, 2011, 6(1): e16037.

[15] Li Nien-chen, Lee Austin, Whitmer Rachel, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis [J]. BMJ, 2010, 8(340): b5465.

[16] Tobias V Lanz, Ding Zhao-qing, Peggy P Ho, et al. Angiotensin II sustains brain inflammation in mice via TGF- β [J]. J Clin Invest, 2010, 120(8): 2782–2794.

[17] H Michael Tucker, Muthoni Kihiko-Ehmann, Sarah Wright, et al. Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition [J]. J Neurochem, 2010, 75(5): 2172–2177.

[18] John W Wright, Jospeh W Harding. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions [J]. Regul Pept, 1995, 59(3): 269-295.

[19] Zhu Y Z, Chimon G N, Zhu Y C, et al. Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats [J]. Neuroreport, 2000, 11(6): 1191-1194.

[20] Li Jun, Juraj Culman, Heide Hortnagl, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury [J]. FASEB J, 2005, 19(6): 617-619.

[21] Lutz Hein, Gregory S Barsh, Richard E Pratt, et al. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice [J]. Nature, 1995, 377(6551): 744-747.

[22] Toshihiro Ichiki, Patricia A Labosky, Chiyo Shiota, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor [J]. Nature, 1995, 377(6551): 748-750.

[23] Wang Jun, Lap Ho, Chen Ling-hong, et al. Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease [J]. J Clin Invest, 2007, 117(11): 3393–3402.

[24] Hajjar Ihab, Meaghan Hart, Chen Yu-ling, et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial [J]. Arch Intern Med, 2012, 172(5): 442-448.

[25] Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydroclorothiazide on cognitive function and quality of life in hypertensive patients [J]. Am J Hypertens, 1999, 12(11 Pt 1): 1130-1134.

[26] Robert Fogari, Paola Preti, Amedeo Mugellini, et al. Influence of losartan and atenolol on cognitive function in very elderly hypertensive patients [J]. Am J Hypertens, 2002, 15(4): 36A.

[27] Lusine Danielyan, Roman Klein, Leah R Hanson, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease [J]. Rejuvenation Res, 2010, 13(2-3): 195–201.

[28] Emmanuelle Duron, Olivier Hanon. Antihypertensive treatments, cognitive decline, and dementia [J]. J Alzheimers Dis, 2010, 20(3): 903-914.

[29] Jan Jozef Braszko, Anna Walesiuk, Przemyslaw Wielgat. Cognitive effects attributed to angiotensin II may result from its conversion to angiotensin IV [J]. J Renin Angiotensin Aldosterone Syst, 2006, 7(3): 168–174.

[30] Davis CJ, Kramar EA, De A, et al. AT4 receptor activation increases intracellular calcium influx and induces a non-N-methyl-D-aspartate dependent form of long-term potentiation [J]. Neuroscience, 2006, 137(4): 1369–1379.

[31] John W Wright, Eniko A Kramar, Elizabeth D Myers, et al. Ethanol-induced suppression of LTP can be attenuated with an angiotensin IV analog [J]. Regul Pept, 2003, 113(1-3): 49–56.

[32] Matthew L Hemming, Dannis J Selkoe. Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor [J]. J Biol Chem, 2005, 280(450): 37644-37650.

[33] John W Wright, Joseph W Harding. The brain angiotensin IV/AT4 receptor system as a new target for the treatment of Alzheimer's disease [J]. Drug Dev Res, 2010, 70(7): 472–480.

[34] Alberto Arregui, Elaine K Perry, Martin Rossor, et al. Angiotensin converting enzyme in Alzheimer’s disease increased activity in caudate nucleus and cortical areas [J]. J Neurochem, 1982, 38(5): 1490–1492.

[35] Dong Yi-Fei, Keiichiro Kataoka, Yoshiko Tokutomi, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease [J]. FASEB J, 2011, 25(9): 2911-2920.

[36] Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels [J]. J Clin Invest, 1990, 86(4): 1343–1346.

[37] Sergei Danilov, Francoise Savoie, Bertrand Lenoir, et al. Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large scale studies [J]. J Hypertens, 1996, 14(6): 719–727.

[38] Roger Cox, Nourdine Bouzekri, Sabrina Martin, et al. Angiotensin-1-converting enzyme (ACE) plasma concentration is influenced by multiple ACE-linked quantitative trait nucleotides [J]. Hum Mol Genet, 2002, 11(23): 2969–2977.

[39] Skidgel R A, Erdös E G. The broad substrate specificity of human angiotensin I converting enzyme [J]. Clin Exp Hypertens A, 1987, 9(2-3): 243-259.

[40] Hu Jian-guo, Akira Igarashi, Makiko Kamata, et al. Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide(Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity [J]. J Biol Chem, 2007, 276(51): 47863-47868.

[41] J Scott Miners, Zoe Van Helmond, Patrick G Kehoe, et al. Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme [J]. Brain Pathol, 2010, 20(4): 794–802.

[42] Zou K, Yamaguchi H, Akaatsu H, et al. Angiotensin- enzyme converts amyloid-protein 1–42(Aβ1–42) to Aβ1–40, and its inhibition enhances brain Aβ deposition [J]. J Neurosci, 2007, 27(32): 8628–8635.

[43] Elizabeth A Eckman, Stephanie K Adams, Frederick J Troendle, et al. Regulation of steady-state β -amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme [J]. J Biol Chem, 2006, 281(41): 30471-30478.

[44] Hemming Matthew L, Selkoe Dennis J, Farris Wesley. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease [J]. Neurobiol Dis, 2007, 26(1): 273-281.

[45] John W Wright, Joseph W Harding. The brain RAS and Alzheimer’s disease [J]. Exp Neurol, 2010, 223(2): 326–333.